|
Indications for Pharmacologic Therapy. |
| National Osteoporosis Foundation [39] |
| Initiate therapy to reduce fracture risk in women with: |
| 1. BMD T-scores below -2.0 by central DXA with no risk factors |
| 2. BMD T-scores below -1.5 by central DXA with one or more risk factors |
| 3. A prior vertebral or hip fracture |
| American Association of Clinical Endocrinologists [47] |
| The following women may benefit from pharmacologic treatment of osteoporosis: |
| 1. Women with postmenopausal osteoporosis (Women with low-trauma fractures and low BMD and women with BMD T-scores of -2.5 and below) |
| 2. Women with borderline low BMD (e.g., T-scores of -1.5 and below) if risk factors are present |
| 3. Women in whom nonpharmacologic preventive measures are ineffective (bone loss continues or low trauma fractures occur) |
|
These recommendations are very similar, with the main difference being the T-score cut-off for treatment in patients with no other risk factors. |
Lewiecki Clinical and Molecular Allergy 2004 2:9 doi:10.1186/1476-7961-2-9 |